{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T13:09:39Z","timestamp":1788959379985,"version":"build-2803163510"},"reference-count":121,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim Corp USA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ctrv.2026.103137","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T15:44:21Z","timestamp":1776440661000},"page":"103137","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Treatments for human epidermal growth factor receptor 2 (HER2)\u2013altered cancers evaluated using a tumor\u2011agnostic approach: A narrative review"],"prefix":"10.1016","volume":"147","author":[{"given":"Guilherme","family":"Harada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie E.","family":"Chaft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison M.","family":"Schram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Pavlakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3611-0258","authenticated-orcid":false,"given":"Yi-Long","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2026.103137_b0005","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.3390\/ijms25021064","article-title":"Molecular targeting of the human epidermal growth factor receptor-2 (HER2) genes across various cancers","volume":"25","author":"Rubin","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ctrv.2026.103137_b0010","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1093\/annonc\/12.suppl_1.S3","article-title":"The basic biology of HER2","volume":"12","author":"Rubin","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103137_b0015","doi-asserted-by":"crossref","first-page":"55","DOI":"10.5858\/2010-0454-RAR.1","article-title":"HER2: biology, detection, and clinical implications","volume":"135","author":"Gutierrez","year":"2011","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.ctrv.2026.103137_b0020","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/j.annonc.2020.08.2335","article-title":"NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents","volume":"31","author":"Laskin","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103137_b0025","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s10555-016-9649-6","article-title":"The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer","volume":"35","author":"Hsu","year":"2016","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.ctrv.2026.103137_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.103997","article-title":"A review of HER2 overexpression and somatic mutations in cancers","volume":"186","author":"Galogre","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ctrv.2026.103137_b0035","unstructured":"U.S. Food and Drug Administration. Approval letter: HERCEPTIN\u00ae (trastuzumab). September 25, 1998. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/1998\/trasgen092598l.pdf. Accessed April 1, 2026."},{"key":"10.1016\/j.ctrv.2026.103137_b0040","unstructured":"U.S. Food and Drug Administration. Approval letter: HERCEPTIN\u00ae (trastuzumab). October 20, 2010., https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2010\/103792s5250ltr.pdf. Accessed January 22, 2025."},{"key":"10.1016\/j.ctrv.2026.103137_b0045","unstructured":"U.S. Food and Drug Administration. Approval letter: TUKYSA\u00ae (tucatinib tablets). January 19, 2023., https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2023\/213411Orig1s004ltr.pdf. Accessed January 22, 2025."},{"key":"10.1016\/j.ctrv.2026.103137_b0050","unstructured":"U.S. Food and Drug Administration. FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive solid tumors. April 5, 2024. 2024. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2. Accessed July 11, 2024."},{"key":"10.1016\/j.ctrv.2026.103137_b0055","doi-asserted-by":"crossref","first-page":"673","DOI":"10.17305\/bb.2024.10641","article-title":"Tumor-type agnostic, targeted therapies make a new step forward: the first tumor-agnostic approval of a HER2-targeted therapy","volume":"24","author":"Vranic","year":"2024","journal-title":"Biomol Biomed"},{"key":"10.1016\/j.ctrv.2026.103137_b0060","unstructured":"Daiichi Sankyo. ENHERTU\u00ae Type II Variation Application Validated in the EU for Previously Treated Patients with HER2 Positive Metastatic Solid Tumors. September 11, 2025. https:\/\/www.daiichisankyo.com\/files\/news\/pressrelease\/pdf\/202509\/20250911_E.pdf. Accessed February 5, 2026."},{"key":"10.1016\/j.ctrv.2026.103137_b0065","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/onc.2017.382","article-title":"A novel HER2 gene body enhancer contributes to HER2 expression","volume":"37","author":"Liu","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.ctrv.2026.103137_b0070","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00428-023-03656-w","article-title":"Standardized pathology report for HER2 testing in compliance with 2023 ASCO\/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer","volume":"484","author":"Ivanova","year":"2024","journal-title":"Virchows Arch"},{"key":"10.1016\/j.ctrv.2026.103137_b0075","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.pathol.2025.02.003","article-title":"HER2-low across solid tumours: different incidences and definitions","volume":"57","author":"Baez-Navarro","year":"2025","journal-title":"Pathology"},{"key":"10.1016\/j.ctrv.2026.103137_b0080","article-title":"Consensus for HER2 alterations testing in non-small-cell lung cancer","volume":"7","author":"Ren","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctrv.2026.103137_b0085","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1158\/1078-0432.CCR-25-1982","article-title":"Advances in targeting HER2 across cancer subtypes: a pan-tumor approach","volume":"32","author":"Adesoye","year":"2026","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103137_b0090","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1111\/bcp.15155","article-title":"Efficacy of targeted therapy in patients with HER2-positive non-small cell lung cancer: a systematic review and meta-analysis","volume":"88","author":"Wu","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ctrv.2026.103137_b0095","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","article-title":"HER2-targeted therapies - a role beyond breast cancer","volume":"17","author":"Oh","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103137_b0100","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.3390\/jpm12101651","article-title":"Deciphering the impact of HER2 alterations on non-small-cell lung cancer: from biological mechanisms to therapeutic approaches","volume":"12","author":"Bontoux","year":"2022","journal-title":"J Pers Med"},{"key":"10.1016\/j.ctrv.2026.103137_b0105","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/852748","article-title":"Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications","volume":"2014","author":"Iqbal","year":"2014","journal-title":"Mol Biol Int"},{"key":"10.1016\/j.ctrv.2026.103137_b0110","doi-asserted-by":"crossref","first-page":"750","DOI":"10.21037\/jgo.2016.06.10","article-title":"The genomics and therapeutics of HER2-positive gastric cancer-from trastuzumab and beyond","volume":"7","author":"Kelly","year":"2016","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.ctrv.2026.103137_b0115","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14174155","article-title":"HER2 in non-small cell lung cancer: a review of emerging therapies","volume":"14","author":"Uy","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctrv.2026.103137_b0120","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41571-024-00924-9","article-title":"HER2-targeted therapies beyond breast cancer - an update","volume":"21","author":"Yoon","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103137_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.103074","article-title":"A pan-cancer analysis of HER2 index revealed transcriptional pattern for precise selection of HER2-targeted therapy","volume":"62","author":"Li","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ctrv.2026.103137_b0130","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.pharmthera.2019.03.010","article-title":"Prevalence and role of HER2 mutations in cancer","volume":"199","author":"Cocco","year":"2019","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.ctrv.2026.103137_b0135","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/cts.12207","article-title":"HER2-positive endometrial cancer subtype carries poor prognosis","volume":"7","author":"\u0141api\u0144ska-Szumczyk","year":"2014","journal-title":"Clin Trans Sci"},{"key":"10.1016\/j.ctrv.2026.103137_b0140","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.3390\/ijms24043720","article-title":"HER2 expression in bladder cancer: a focused view on its diagnostic, prognostic, and predictive role","volume":"24","author":"Sanguedolce","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ctrv.2026.103137_b0145","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1093\/annonc\/mdy100","article-title":"Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer","volume":"29","author":"Siena","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103137_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2023.106612","article-title":"HER2-targeted therapies for salivary gland cancers","volume":"148","author":"Filippini","year":"2024","journal-title":"Oral Oncol"},{"key":"10.1016\/j.ctrv.2026.103137_b0155","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1634\/theoncologist.2019-0922","article-title":"HER2 overexpression as a poor prognostic determinant in resected biliary tract cancer","volume":"25","author":"Vivaldi","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2026.103137_b0160","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/JTO.0b013e3181f26266","article-title":"The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: a meta-analysis of published data","volume":"5","author":"Liu","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2026.103137_b0165","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s12253-014-9847-x","article-title":"Prognostic value of increased HER2 expression in cancers of pancreas and biliary tree","volume":"21","author":"Ata","year":"2015","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.ctrv.2026.103137_b0170","article-title":"The frequency and clinical impact of HER2 alterations in lung adenocarcinoma","volume":"12","author":"Kim","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ctrv.2026.103137_b0175","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s10549-015-3334-2","article-title":"Quantitative assessment of HER2 amplification in HER2-positive breast cancer: its association with clinical outcomes","volume":"150","author":"Xuan","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2026.103137_b0180","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.cllc.2024.09.001","article-title":"Use of oncogene overlap by tissue-based next-generation sequencing to explore the mutational landscape and survival impact of HER2, KRAS and MET copy-number gain in nonsmall cell lung cancer","volume":"25","author":"Watson","year":"2024","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ctrv.2026.103137_b0185","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.breast.2022.02.002","article-title":"HER2 copy number quantification in primary tumor and cell-free DNA provides additional prognostic information in HER2 positive early breast cancer","volume":"62","author":"Chen","year":"2022","journal-title":"Breast"},{"key":"10.1016\/j.ctrv.2026.103137_b0190","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1111\/1759-7714.13419","article-title":"Mutational landscape and characteristics of ERBB2 in non-small cell lung cancer","volume":"11","author":"Wei","year":"2020","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.ctrv.2026.103137_b0195","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2017-000279","article-title":"Activating HER2 mutations as emerging targets in multiple solid cancers","volume":"2","author":"Connell","year":"2017","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctrv.2026.103137_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2019.09.001","article-title":"Pan-cancer landscape and analysis of ERBB2 mutations identifies poziotinib as a clinically active inhibitor and enhancer of T-DM1 activity","volume":"36","author":"Robichaux","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctrv.2026.103137_b0205","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S1470-2045(24)00140-2","article-title":"Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study","volume":"25","author":"Li","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103137_b0210","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1200\/JCO.2018.77.9777","article-title":"Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: results from a phase II basket trial","volume":"36","author":"Li","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103137_b0215","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in HER2-mutant non-small cell lung cancer","volume":"386","author":"Li","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103137_b0220","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1016\/j.jtho.2025.07.129","article-title":"Final analysis results and patient-reported outcomes from DESTINY-Lung02\u2014a dose-blinded, randomized, phase 2 study of trastuzumab deruxtecan in patients with HER2-mutant metastatic NSCLC","volume":"20","author":"J\u00e4nne","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2026.103137_b0225","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nature25475","article-title":"HER kinase inhibition in patients with HER2- and HER3-mutant cancers","volume":"554","author":"Hyman","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2026.103137_b0230","article-title":"Phase II study of afatinib in patients with tumors with human epidermal growth factor receptor 2-activating mutations: results from the National Cancer Institute\u2013Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) subprotocol EAY131-B","volume":"6","author":"Bedard","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ctrv.2026.103137_b0235","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1200\/JCO.22.02636","article-title":"MyPathway human epidermal growth factor receptor 2 basket study: pertuzumab + trastuzumab treatment of a tissue-agnostic cohort of patients with human epidermal growth factor receptor 2-altered advanced solid tumors","volume":"42","author":"Sweeney","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103137_b0240","unstructured":"U.S. Food and Drug Administration. ZIIHERA\u00ae (zanidatamab-hrii). Highlights of Prescribing Information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2024\/761416Orig1s000Lbl.pdf. Accessed April 1, 2026."},{"key":"10.1016\/j.ctrv.2026.103137_b0245","unstructured":"U.S. Food and Drug Administration. BIZENGRI\u00ae (zenocutuzumab-zbco). Highlights of Prescribing Information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761352s001lbl.pdf. Accessed April 1, 2026."},{"key":"10.1016\/j.ctrv.2026.103137_b0250","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40364-024-00565-1","article-title":"HER2-targeted therapies in cancer: a systematic review","volume":"12","author":"Zhu","year":"2024","journal-title":"Biomarker Res"},{"key":"10.1016\/j.ctrv.2026.103137_b0255","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1200\/JCO.2017.75.3780","article-title":"Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study","volume":"36","author":"Hainsworth","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103137_b0260","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1158\/1078-0432.CCR-23-0633","article-title":"Trastuzumab and pertuzumab in patients with non-breast\/gastroesophageal HER2-amplified tumors: results from the NCI-MATCH ECOG-ACRIN trial (EAY131) Subprotocol","volume":"30","author":"Connolly","year":"2024","journal-title":"J Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103137_b0265","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10120-022-01335-4","article-title":"Pertuzumab, trastuzumab, and chemotherapy in HER2-positive gastric\/gastroesophageal junction cancer: end-of-study analysis of the JACOB phase III randomized clinical trial","volume":"26","author":"Tabernero","year":"2023","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.ctrv.2026.103137_b0270","volume":"41","author":"Wagner","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103137_b0275","doi-asserted-by":"crossref","first-page":"S614","DOI":"10.1016\/j.annonc.2021.08.1079","article-title":"SGNTUC-019: phase II basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations","volume":"32","author":"Reck","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103137_b0280","doi-asserted-by":"crossref","first-page":"S165","DOI":"10.1016\/j.ygyno.2023.06.170","article-title":"A phase 2 basket study of tucatinib and trastuzumab in solid tumors with human epidermal growth factor receptor 2 alterations: uterine and cervical cancer cohorts (SGNTUC-019, trial in progress)","volume":"176","author":"Monk","year":"2023","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ctrv.2026.103137_b0285","doi-asserted-by":"crossref","first-page":"5569","DOI":"10.1200\/JCO.23.00606","article-title":"Tucatinib and trastuzumab for previously treated human epidermal growth factor receptor 2-positive metastatic biliary tract cancer (SGNTUC-019): a phase II basket study","volume":"41","author":"Nakamura","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103137_b0290","unstructured":"U.S. Food and Drug Administration. PHESGO\u00ae (pertuzumab\/trastuzumab\/hyaluronidase-zzxf). Highlights of Prescribing Information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761170s007lbl.pdf. Accessed April 1, 2026."},{"key":"10.1016\/j.ctrv.2026.103137_b0295","unstructured":"U.S. Food and Drug Administration. TUKYSA\u00ae (tucatinib). Highlights of Prescribing Information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/213411s004lbl.pdf. Accessed April 1, 2026."},{"key":"10.1016\/j.ctrv.2026.103137_b0300","unstructured":"U.S. Food and Drug Administration. HERNEXEOS\u00ae (zongertinib tablets). Highlights of Prescribing Information. 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/219042s001lbl.pdf. Accessed March 5, 2026."},{"key":"10.1016\/j.ctrv.2026.103137_b0305","unstructured":"U.S. Food and Drug Administration. Hyrnuo\u00ae (sevabertinib). Highlights of Prescribing Information. Assessed Match 30:2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/219972s000lblCorrected.pdf."},{"key":"10.1016\/j.ctrv.2026.103137_b0310","unstructured":"U.S. Food and Drug Administration. ENHERTU\u00ae (fam-trastuzumab deruxtecan-nxki). Highlights of Prescribing Information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761139s038s042lbl.pdf. Accessed March 30, 2026."},{"key":"10.1016\/j.ctrv.2026.103137_b0315","unstructured":"U.S. Food and Drug Administration. KADCYLA\u00ae (ado-trastuzumab emtansine). Highlights of Prescribing Information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/125427s125lbl.pdf. Accessed March 30, 2026."},{"key":"10.1016\/j.ctrv.2026.103137_b0320","doi-asserted-by":"crossref","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","article-title":"Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice guidelines in Oncology","volume":"22","author":"Riely","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ctrv.2026.103137_b0325","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1470-2045(24)00064-0","article-title":"Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial","volume":"25","author":"Smit","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103137_b0330","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.3501","article-title":"Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing\/amplified (HER2+) metastatic colorectal cancer (mCRC): primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study","volume":"41","author":"Raghav","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103137_b0335","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103137_b0340","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1093\/annonc\/mdz291","article-title":"Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric\/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q","volume":"30","author":"Jhaveri","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103137_b0345","article-title":"Final analysis of multi-histology basket trial expansion of ado-trastuzumab emtansine in patients with HER2 amplified cancers","volume":"41","author":"Liu","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103137_b0350","doi-asserted-by":"crossref","first-page":"S480","DOI":"10.1016\/j.annonc.2021.08.554","article-title":"271P First-in-human, phase I dose escalation and expansion study of anti-HER2 ADC MRG002 in patients with HER2 positive solid tumors","volume":"32","author":"Guo","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103137_b0355","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41467-023-36399-y","article-title":"Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers","volume":"14","author":"Harding","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctrv.2026.103137_b0360","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ygyno.2023.12.004","article-title":"Targeting HER2-mutant metastatic cervical cancer with neratinib: final results from the phase 2 SUMMIT basket trial","volume":"181","author":"Friedman","year":"2024","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ctrv.2026.103137_b0365","unstructured":"U.S. Food and Drug Administration. NERLYNX\u00ae (neratinib tablets). Highlights of Prescribing Information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/208051s009lbl.pdf. Accessed March 29, 2026."},{"key":"10.1016\/j.ctrv.2026.103137_b0370","unstructured":"U.S. Food and Drug Administration. GILOTRIF\u00ae (afatinib tablets). Highlights of Prescribing Information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/201292s017lbl.pdf. Accessed April 1, 2026."},{"key":"10.1016\/j.ctrv.2026.103137_b0375","article-title":"Afatinib in patients (pts) with solid tumors with neuregulin 1 (NRG1) fusions: results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study","volume":"42","author":"Ahnert","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103137_b0380","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1056\/NEJMoa2503704","article-title":"Zongertinib in previously treated HER2-mutant non-small-cell lung cancer","volume":"392","author":"Heymach","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103137_b0385","unstructured":"U.S. Food and Drug Administration. HERNEXEOS\u00ae (zongertinib tablets). Highlights of Prescribing Information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/219042s001lbl.pdf. Accessed March 30, 2026."},{"key":"10.1016\/j.ctrv.2026.103137_b0390","unstructured":"Boehringer Ingelheim. Boehringer\u2019s HERNEXEOS\u00ae approved in China as first oral targeted therapy for previously treated patients with HER2-mutant advanced NSCLC. September 1, 2025. https:\/\/www.boehringer-ingelheim.com\/human-health\/cancer\/lung-cancer\/hernexeos-approved-china-targeted-therapy-nsclc. Accessed March 30, 2026."},{"key":"10.1016\/j.ctrv.2026.103137_b0395","unstructured":"Boehringer Ingelheim. Boehringer Ingelheim gets approval for HERNEXEOS\u00ae in Japan. September 19, 2025. https:\/\/www.boehringer-ingelheim.com\/human-health\/cancer\/lung-cancer\/boehringer-ingelheim-gets-approval-hernexeos-japan. Accessed March 30, 2026."},{"key":"10.1016\/j.ctrv.2026.103137_b0400","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1200\/JCO-24-01727","article-title":"HER2-selective tyrosine kinase inhibitor, zongertinib (BI 1810631), in patients with advanced\/metastatic solid tumors with HER2 alterations: a phase Ia dose-escalation study","volume":"43","author":"Heymach","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103137_b0405","doi-asserted-by":"crossref","first-page":"S185","DOI":"10.1016\/j.annonc.2025.05.508","article-title":"491P Zongertinib in HER2-altered gastrointestinal cancers: Preclinical activity and clinical findings from a phase Ia study","volume":"36","author":"Yoh","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103137_b0410","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.1023","article-title":"Zongertinib in HER2-altered breast cancer: Preclinical activity and preliminary results from a phase Ia dose-escalation study","volume":"43","author":"Berz","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103137_b0415","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1016\/S1470-2045(15)70057-4","article-title":"Response assessment criteria for brain metastases: proposal from the RANO group","volume":"16","author":"Lin","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103137_b0420","first-page":"1","article-title":"Zongertinib in treatment-na\u00efve patients with HER2-mutant NSCLC, including those with active brain metastases: Beamion LUNG-1","volume":"11","author":"Heymach","year":"2026","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103137_b0425","unstructured":"ClinicalTrials.gov. Beamion PANTUMOR-1: a study to test whether zongertinib helps people with advanced cancers with HER2 alterations. 2025. https:\/\/clinicaltrials.gov\/study\/NCT06581432."},{"key":"10.1016\/j.ctrv.2026.103137_b0430","unstructured":"ClinicalTrials.gov. Beamion BCGC-1: a study to find a suitable dose of zongertinib in combination with trastuzumab deruxtecan or with trastuzumab emtansine and to test whether it helps people with different types of HER2+ cancer that has spread. 2025. https:\/\/clinicaltrials.gov\/study\/NCT06324357."},{"key":"10.1016\/j.ctrv.2026.103137_b0435","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1080\/14796694.2025.2569553","article-title":"Beamion BCGC-1: phase Ib\/II trial of zongertinib for advanced HER2-positive breast or gastroesophageal cancers","volume":"21","author":"Hurvitz","year":"2025","journal-title":"Future Oncol"},{"key":"10.1016\/j.ctrv.2026.103137_b0440","article-title":"Retrospective study on the efficacy and safety of pyrotinib-based therapy for HER2-positive nonbreast advanced solid tumors","volume":"2022","author":"Wang","year":"2022","journal-title":"J Oncol"},{"key":"10.1016\/j.ctrv.2026.103137_b0445","article-title":"Safety and efficacy of pyrotinib in patients with NSCLC and other advanced solid tumors with activating HER2 alterations: a phase I basket trial","volume":"38","author":"Li","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103137_b0450","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1038\/s41591-023-02461-x","article-title":"First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial","volume":"29","author":"Liu","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2026.103137_b0455","unstructured":"ClinicalTrials.gov. A study to learn more about how well treatment with BAY2927088 tablets works and how safe it is in participants who have a solid tumor with mutations of the human epidermal growth factor receptor 2 (HER2) (panSOHO). 20 ed2025. https:\/\/clinicaltrials.gov\/study\/NCT06760819."},{"key":"10.1016\/j.ctrv.2026.103137_b0460","unstructured":"Bayer. New results from the investigational agent BAY 2927088 in HER2-mutant non-small cell lung cancer (NSCLC) presented at WCLC. 2024. https:\/\/www.bayer.com\/en\/us\/news-stories\/non-small-cell-lung-cancer."},{"key":"10.1016\/j.ctrv.2026.103137_b0465","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1056\/NEJMoa2511065","article-title":"Sevabertinib in advanced HER2-mutant non-small-cell lung cancer","volume":"393","author":"Le","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103137_b0470","unstructured":"ClinicalTrials.gov. A Phase 1\/1b study of IAM1363 in HER2 cancers. 2024. https:\/\/clinicaltrials.gov\/study\/NCT06253871."},{"key":"10.1016\/j.ctrv.2026.103137_b0475","doi-asserted-by":"crossref","first-page":"S575","DOI":"10.1016\/j.annonc.2025.08.1507","article-title":"938P a phase I\/Ib study of IAM1363, a selective and brain penetrant HER2 inhibitor in participants (pts) with advanced cancers harboring HER2 alterations","volume":"36","author":"Chandana","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103137_b0480","unstructured":"ClinicalTrials.gov. A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1) 2025. https:\/\/www.clinicaltrials.gov\/study\/NCT06521554."},{"key":"10.1016\/j.ctrv.2026.103137_b0485","doi-asserted-by":"crossref","first-page":"S769","DOI":"10.1016\/j.annonc.2023.09.2366","article-title":"A global phase 1b study of ORIC-114, a highly selective, brain penetrant EGFR and HER2 inhibitor, in patients with advanced solid tumors harboring EGFR exon 20 or HER2 alterations","volume":"34","author":"Hong","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103137_b0490","unstructured":"ClinicalTrials.gov. Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration. 2025. https:\/\/clinicaltrials.gov\/study\/NCT05315700."},{"key":"10.1016\/j.ctrv.2026.103137_b0495","doi-asserted-by":"crossref","first-page":"5334","DOI":"10.1021\/acs.jmedchem.1c00710","article-title":"Discovery of SPH5030, a selective, potent, and irreversible tyrosine kinase inhibitor for HER2-amplified and her2-mutant cancer treatment","volume":"65","author":"Li","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.ctrv.2026.103137_b0500","unstructured":"ClinicalTrials.gov. SPH5030 tablets in subjects with advanced HER2-positive solid tumors. 2024. https:\/\/www.clinicaltrials.gov\/study\/NCT05245058."},{"key":"10.1016\/j.ctrv.2026.103137_b0505","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.1041","article-title":"Preclinical and early clinical data of ZN-1041 in combination with trastuzumab deruxtecan to treat breast cancer with or without CNS metastases","volume":"41","author":"Anders","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103137_b0510","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1200\/JCO.2023.41.16_suppl.1040","article-title":"Preclinical and early clinical data of ZN-1041, a best-in-class BBB penetrable HER2 inhibitor to treat breast cancer with CNS metastases","volume":"41","author":"Ma","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103137_b0515","unstructured":"ClinicalTrials.gov. A phase 1 trial of ZN-A-1041 enteric capsules or combination in patients with HER2-positive advanced solid tumors. 2024. https:\/\/www.clinicaltrials.gov\/study\/NCT05593094."},{"key":"10.1016\/j.ctrv.2026.103137_b0520","unstructured":"ClinicalTrials.gov. Trial of ZN-A-1041 enteric capsules in patients with HER2-positive advanced solid tumors. 2024. https:\/\/clinicaltrials.gov\/study\/NCT04487236."},{"key":"10.1016\/j.ctrv.2026.103137_b0525","unstructured":"ClinicalTrials.gov. A Study of VRN101099 in Patients With HER2-Positive Solid Tumors. 2025. https:\/\/clinicaltrials.gov\/study\/NCT06806982."},{"key":"10.1016\/j.ctrv.2026.103137_b0530","unstructured":"ClinicalTrials.gov. A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors. 2025. https:\/\/clinicaltrials.gov\/study\/NCT07361562."},{"key":"10.1016\/j.ctrv.2026.103137_b0535","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(22)00621-0","article-title":"Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study","volume":"23","author":"Meric-Bernstam","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103137_b0540","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S1470-2045(23)00242-5","article-title":"Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study","volume":"24","author":"Harding","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103137_b0545","doi-asserted-by":"crossref","DOI":"10.1002\/cac2.70026","article-title":"Phase II study evaluating the safety and efficacy of neratinib and trastuzumab biosimilar in patients with HER2 mutated advanced solid tumors: KCSG AL20-17\/KM23 trial","author":"Lee","year":"2025","journal-title":"Cancer Commun (Lond)"},{"key":"10.1016\/j.ctrv.2026.103137_b0550","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1056\/NEJMoa1413513","article-title":"Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer","volume":"372","author":"Swain","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103137_b0555","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1703643","article-title":"Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer","volume":"377","author":"von Minckwitz","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103137_b0560","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.3142","article-title":"Pertuzumab plus trastuzumab (P+T) in patients (pts) with solid tumors with ERBB2 or ERBB3 amplification (amp) or mutations (mut): results from the Targeted Agent and Profiling utilization Registry (TAPUR) study","volume":"42","author":"Dib","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103137_b0565","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/s41591-024-03462-0","article-title":"Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial","volume":"31","author":"Okines","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2026.103137_b0570","unstructured":"American Cancer Society. Tumor-agnostic drugs. 2026. https:\/\/www.cancer.org\/cancer\/managing-cancer\/treatment-types\/tumor-agnostic-drugs.html. Accessed April 1, 2026."},{"key":"10.1016\/j.ctrv.2026.103137_b0575","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.annonc.2024.07.730","article-title":"The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development","volume":"35","author":"Westphalen","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103137_b0580","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12885-022-10421-w","article-title":"Umbrella review of basket trials testing a drug in tumors with actionable genetic biomarkers","volume":"23","author":"Haslam","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2026.103137_b0585","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3390\/ph16040614","article-title":"Agnostic approvals in oncology: getting the right drug to the right patient with the right genomics","volume":"16","author":"Tateo","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.ctrv.2026.103137_b0590","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1001\/jamaoncol.2025.1791","article-title":"A real-world experience in pan-tumor testing for HER2 IHC in more than 65 000 solid tumors","volume":"11","author":"Bryant","year":"2025","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctrv.2026.103137_b0595","doi-asserted-by":"crossref","DOI":"10.1200\/PO-25-00413","article-title":"HER2 protein overexpression, mRNA expression, and DNA amplification across solid tumors: comparison of next-generation sequencing-based assays with immunohistochemistry","volume":"10","author":"Nagamine","year":"2026","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ctrv.2026.103137_b0600","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1200\/JCO.23.02626","article-title":"Trastuzumab deruxtecan in advanced solid tumors with human epidermal growth factor receptor 2 amplification identified by plasma cell-free DNA testing: a multicenter, single-arm, phase II basket trial","volume":"42","author":"Yagisawa","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103137_b0605","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf152","article-title":"The present and future of precision oncology and tumor-agnostic therapeutic approaches","volume":"30","author":"Shah","year":"2025","journal-title":"Oncologist"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226000514?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226000514?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T02:48:45Z","timestamp":1781059725000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737226000514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":121,"alternative-id":["S0305737226000514"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103137","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatments for human epidermal growth factor receptor 2 (HER2)\u2013altered cancers evaluated using a tumor\u2011agnostic approach: A narrative review","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103137","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103137"}}